Suchergebnisse - "Virtanen, Anniina"

PubPharm (8)

1

Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2023

von Virtanen, A. | Palmroth, M. | Liukkonen, S. | +4

2

Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening

enthalten in: SLAS discovery : advancing life sciences R & D | 2023

von Pölläniemi, A. | Virtanen, A. | Silvennoinen, O. | +1

3

New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation

enthalten in: Cell chemical biology | 2023

von Arwood, M. | Liu, Y. | Harkins, S. | +22

4

Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response

enthalten in: Clinical and experimental immunology | 2022

von Valli, A. | Kuuliala, K. | Virtanen, A. | +7

5

Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response

enthalten in: Frontiers in immunology | 2021

von Palmroth, M. | Kuuliala, K. | Peltomaa, R. | +7

6

The regulation of JAKs in cytokine signaling and its breakdown in disease

enthalten in: Cytokine | 2019

von Hammarén, H. | Virtanen, A. | Raivola, J. | +1

7

Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations

enthalten in: The Journal of allergy and clinical immunology | 2019

von Hammarén, H. | Virtanen, A. | Abraham, B. | +3

8

Nucleotide-binding mechanisms in pseudokinases

enthalten in: Bioscience reports | 2015

von Hammarén, H. | Virtanen, A. | Silvennoinen, O.

1
[1]